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An Animal Model for Somatic Gene Therapy 
In this issue (p. 171), Petersen et al describe an animal model for 
somatic gene therapy that uses genetically modified 3T3 fibroblasts 
implanteq subcutaneously into athymic mice. Introducing absent or 
deficient genes into skin cells has been proposed as a means of gene 
therapy because both fibroblasts and keratinocytes are readily 
obtained and expanded in culture. Additionally, such expanded 
cultures can be easily grafted back onto the host. Here, Petersen 
and colleagues report on such a system. Employing a vector derived 
from a recombinant retroviru~, they introduced the gene for human 
transferrin (hTf) into cultured skin fibroblasts. Then they employed 
a new technique, cloning these genetically altered cells to select for 
ones producing high levels of hTf. The selected cells were seeded 
into a nylon matrix and implanted subcutaneously into the flanks of 
athymic mice. In other somatic models, researchers have seen loss 
of gene expression within two months. In this study, however, the 
authors report that plasma levels of hTf remained elevated above 
normal for the full 45 months until the implant was removed. In 
addition, the immunosuppressed state of the athymic mice permit-
ted the 3T3 cells to form tumors at the implant site, and plasma 
levels ofhTf correlated with the size of the tumor until the tumors 
became cystic centrally. Such correlation may be useful in predict-
ing the number of genetically modified cells needed to correct 
diseases characterized by plasma protein deficiencies. After removal 
of the tumor, the hTf level fell to zero after four days. Thus, this 
model demonstrates that fibroblasts are potentially useful for 
carrying selected genes in human gene therapy. 
Specific Suppression of Lupus-Like Graft- Versus-Host Disease 
Using an established graft-versus-host (GVH) mouse model of 
lupus, Girardi and co-workers (p. 177) report that vaccination of 
these mice with effector T cells, which have been treated with 
8-methoxypsoralen (8-MOP) and ultraviolet A irradiation (UV A), 
signifIcantly ameliorates the disease. In this model, injection of 
parental spleen and lymph node cells into first generation mice 
produces a GVH reaction of a chronic stimulatory type that results 
in the development oflupus-like autoimmune disease. This disease 
is similar to the human disease in that it produces anti-nuclear 
antibodies (ANA), glomerulonephritis, ascites, and decreased sur-
vival. Unlike some mouse models oflupus, the disease in this model 
is produced by a distinct host-antigen-specific population of T-
helper cells. Apparently, the donor graft T-helper cells provide help 
for normally quiescent autoreactive host B cells to stimulate the 
production of autoantibodies. The investigators here enriched for 
such T cells, treated them with 8-MOP and UV A, secondarily 
stimulated them in vitro with target cells and interleukin-1 (IL-2), 
then used them to vaccinate GVH mice prior to or after disease 
initiation. They found that GVH mice inoculated with such treated 
cells showed decreases in ANA titer, ascites, and death. Further-
more, they found no evidence of kidney disease in the treated mice. 
These findings suggest that 8-MOP/UV A-attenuated effector T 
cells can be used to decrease the severity of T -cell-mediated 
autoimmune diseases. 
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Lymphoid Cells Are the Likely Targets of Methotrexate 
Using an in vitro model system, Jeffes and colleagues (p. 183) show 
that low doses of methotrexate (MTX) kill a greater percentage of 
proliferating macrophages and T cells than of proliferating epithe-
lial cells. Methotrexate is one of the most effective treatments for 
psoriasis. It is a cytotoxic agent that mediates its effect through 
proliferating cells. Previously, it was thought to affect primarily 
proliferating epidermal cells in the psoriatic plaques, but recent 
evidence has shown that lymphoid cells also proliferate in these 
lesions. To determine if MTX also affected these lymphoid cells, 
Jeffes and his co.-workers exposed cultures of lymphoid cells and 
epithelial cells to doses of MTX that mimicked the MTX blood 
level during low-dose once-weekly psoriatic therapy. They found 
that both proliferating macrophages and T cells were about 100 
times more sensitive to the cytotoxic effects of MTX than were 
proliferating HeLa cells and HaCaT cells, both established epithe-
lial cell lines. Furthermore, they found that both types oflymphoid 
cells were 1000 times more sensitive than normal human keratino-
cytes to MTX-mediated killing. Extrapolating to the in vivo situa-
tion, the authors predict that with normal clinical doses of MTX 
approximately 95% of the lymphoid cells would be killed, whereas 
only about 10% of the epidermal cells would be affected. The in 
vitro data reported here suggest that proliferating lymphoid cells are 
the likely cellular targets of MTX during psoriatic therapy. 
SKALP: A Serum Marker for Disease Activity in Psoriasis 
SKALP (skin-derived antileukoproteinase, also known as ELAFIN) 
is strongly induced in suprabasal keratinocytes in diseases associated 
with inflammation, including psoriasis. In this issue, Alkemade et aT 
(p. 189) report that the serum levels of SKALP in patients with 
psoriasis correlate with disease activity. SKALP is nearly undetect-
able in normal human epidermis but is strongly expressed in skin 
showing inflammation, such as in psoriasis. SKALP can be detected 
because, although it becomes crosslinked to the cornified layers of 
the epidermis, a fragment is cleaved off, and this fragment can be 
extracted from the skin sample. Additionally, SKALP has been 
detected in the urine of psoriatic patients, and here the authors 
report that SKALP is also found in the serum. Thus, SKALP can be 
detected in the systemic circulation of patients with inflammatory 
skin diseases . The authors use tlus phenomenon to monitor cyclo-
sporin A treatment of patients with severe and chronic psoriasis. 
They measured the serum levels of SKALP for sixteen weeks and 
found that as patients showed improvement, serum levels of 
SKALP decreased. In fact, the decrease correlated well with the 
clinical scores the physicians gave the patients. It remains to be 
determined whether this finding will be useful in predicting the 
course or understanding the pathogenesis of psoriasis. 
Implication of Singlet Oxygen on Photoaging 
Singlet oxygen is a very reactive, damaging molecule with a short 
lifetime that is frequently postulated to be produced when mam-
malian cells have been irradiated with ultraviolet radiation (UV). In 
this issue, Wlascheck et al (p. 194) report that singlet oxygen 
induces the production of collagenase in cultured human skin 
fibroblasts, and that this induction resembles the effects of UV A. 
Chronic exposure of the UV irradiation in sunlight has been shown 
to increase photoaging of skin. This photoaging is characterized by 
loss of interstitial collagens, which are responsible for mechanical 
and biophysical properties of the skin. The loss of collagen is likely 
due to the overproduction of collagen-degrading enzymes, such as 
the matrix metalloproteinases (MMPs). It has previously been 
shown that MMPs can be induced by UV in vitro and that the 
induction is mediated by cytokines. Here, the authors examine the 
effect of singlet oxygen on the production of MMP-l, interstitial 
collagenase, in cultured dermal fibroblasts . Using a "clean" source 
of singlet oxygen, they show that this molecule induces MMP-l, 
both mRNA and protein, in vitro. Furthermore, because these 
effects resemble those found after UV A, they conclude that singlet 
oxygen may be a mediator of collagenase induction by UV A. These 
findings may be of particular relevance to future development of 
UV photoprotective agents for skin. 
IGF with IGF-Binding Protein Stimulates Wound Healing in Animal Models 
Tsuboi and colleagues (p. 199) demonstrate that the administration 
of recombinant human insulin-like growth factor-I (rhIGF-I along 
with recombinant human insulin-like growth factor- binding pro-
tein-l (rhIGFBP-l) stimulates wound healing. Recent studies have 
suggested that several growth factors are involved in the healing 
process and that exogenous application of these growth factors may 
promote wound healing in vivo. One such growth factor, insulin-
like growth factor-I (IGF-I), is known to stimulate keratinocyte 
growth in a paracrine fashion and promote formation of granulation 
tissue in animal models. By evaluating the extent of re-epithelial-
ization, the area of granulation tissue, and the number of capillaries 
formed, Tsuboi et al assessed the repair of full-thickness wounds on 
the backs of diabetic mice and the ears of normal rabbits. They 
found that using a combination of both rhIGFf-I and rhIGFBP-l 
produced faster healing than in normal mice or mice treated with 
the growth factor alone without the binding protein. Although the 
precise mechanism by which the binding protein stimulates the 
growth factor is not clear, these results suggest that the co-
administration of growth factor and its binding protein may be the 
clinical therapy of choice to enhance wound repair. 
